Cotinga Pharmaceuticals Enterprise value
What is the Enterprise value of Cotinga Pharmaceuticals?
The Enterprise value of Cotinga Pharmaceuticals, Inc. is $1.07M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with enterprise value similar to Cotinga Pharmaceuticals
- Core Canadian Dividend Trust has Enterprise value of $1.04M
- Q Technology has Enterprise value of $1.05M
- Predictiv AI has Enterprise value of $1.06M
- Orestone Mining has Enterprise value of $1.06M
- RNY Property Trust has Enterprise value of $1.06M
- Zinc One Resources has Enterprise value of $1.06M
- Cotinga Pharmaceuticals has Enterprise value of $1.07M
- Thred has Enterprise value of $1.07M
- BPM Minerals has Enterprise value of $1.07M
- Roots Sustainable Agricultural Technologies has Enterprise value of $1.07M
- Immobiliere Distri-Land NV has Enterprise value of $1.07M
- Pangolin Diamonds has Enterprise value of $1.08M
- Vintana Plc has Enterprise value of $1.09M